INFLAMMATION AND AUTOIMMUNITY
Inflammation is the body’s natural defense against potential danger signals and tissue damage. In some instances, malfunctions in the immune system lead to uncontrolled inflammation and the destruction of the body’s own cells and tissues—resulting in the development of rheumatological, dermatological or gastroenterological diseases.
The goal of Incyte’s inflammation and autoimmunity (IAI) development group is to identify, target and modulate immunological pathways driving uncontrolled inflammation and the destruction of the body’s own cells and tissues. In doing so we hope to restore normal immune function to bring the body closer to homeostasis.
Research has shown that overactivation of the janus kinase (JAK) pathway is critical to the pathogenesis of many immune-mediated conditions. We are working to leverage our cross-program knowledge of the JAK-STAT pathway to explore the potential of JAK inhibition in a number of immune-mediated conditions where we believe we may be able to address unmet patient needs, including several dermatology and gastroenterology conditions.
Phosphoinositide 3-kinase delta (PI3Kδ) signaling is central to B cell biology and plays a significant role in B cell activation, cytokine release and antibody production. At Incyte, we are investigating PI3Kδ inhibition across a variety of B cell mediated and antibody-driven diseases beyond oncology where current therapies do not sufficiently address the unmet need.
Overall, our IAI team utilizes their broad immunological understanding of disease and cross functional knowledge of our programs to identify innovative approaches to treating inflammatory and autoimmune diseases.